VivoSeq
Oncology

Carcinoma, Non-Small-Cell Lung

51

Pipeline Programs↗

30

Active Trials↗

22

Companies Involved↗

Carcinoma, Non-Small-Cell Lung is a moderately active landscape with 51 programs across 22 companies. The most active players are Johnson & Johnson Enterprise Innovation Inc., Parkedale, Kenvue Brands. 17 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

25/100

Mech. Concentration

8/100

Completion Rate

75/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Johnson & Johnson Enterprise Innovation Inc.

3 programs

Phase 2P

Parkedale

1 program

Phase 2K

Kenvue Brands

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

36 of 48 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody817%Antibody–drug conjugate48%

Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 91% of 57 pipeline programs.

Analysis

Trial Status

34

clinical trials

Recruiting17 · 50%
Active, not recruiting11 · 32%
Completed3 · 9%
Not yet recruiting2 · 6%
Terminated1 · 3%

Clinical Trials

Trial Activity

34 trials

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Recruiting·MMirati Therapeutics Inc.·Phase 3·NCT06875310·630 enrolled
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy in China: A Multicenter, Prospective Cohort Study
Recruiting·Roche logoRoche·N/A·NCT06862869·800 enrolled
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT06119581·1,264 enrolled
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
Recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT06890598·700 enrolled
KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06780085·96 enrolled
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT07586202·68 enrolled
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Preclinical·NCT07227025·60 enrolled
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 2·NCT06667908·130 enrolled
Prospective, Multi Country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Approved Amivantamab-containing Regimens Under Standard Clinical Practice
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07230691·380 enrolled
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT06667076·480 enrolled
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer
Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT06116786·126 enrolled
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
Recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT06623422·680 enrolled
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Recruiting·Pfizer logoPfizer·Phase 1·NCT04389632·1,006 enrolled
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT05498428·520 enrolled
KEYMAKER-U01 Substudy 01A: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Cancer (NSCLC)
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT04165070·450 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)